Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 4/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.44 |
| ▸ | MC4R | P32245 | 3/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | PRKX | P51817 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975394 | 1.00 | RORC (0.52) | RORCF10S1PR5S1PR1MC4R | |
| SCHEMBL1993817 | 1.00 | RORC (0.52) | RORCF10S1PR5S1PR1MC4R | |
| SCHEMBL3337004 | 1.00 | RORC (0.52) | RORCF10S1PR5S1PR1MC4R | |
| SCHEMBL16780160 | 1.00 | RORC (0.52) | RORCF10S1PR5S1PR1MC4R | |
| SCHEMBL1344715 | 0.91 | RORC (0.50) | RORCF10S1PR5S1PR1MC4R | |
| SCHEMBL1713654 | 0.90 | RORC (0.54) | RORCF10S1PR5S1PR1MC4R | |
| SCHEMBL3342666 | 0.90 | RORC (0.54) | RORCF10S1PR5S1PR1MC4R | |
| SCHEMBL1986464 | 0.90 | RORC (0.54) | RORCF10S1PR5S1PR1MC4R | |
| SCHEMBL1984539 | 0.90 | RORC (0.54) | RORCF10S1PR5S1PR1MC4R | |
| SCHEMBL4162044 | 0.89 | RORC (0.55) | RORCF10S1PR5S1PR1PRKX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096520-B2 | Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators | ABT HOLDING COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ABT HOLDING COMPANY (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716324-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-2513052-A1 | PYRROLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-2513084-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252859-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | ATHERSYS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8232311-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2379500-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011085886-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| US-20110172283-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | BENNANI YOUSSEF L | 2011-07-14 | — | — | US | disclosed |
| WO-2011073160-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-7935830-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| WO-2010069793-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. | 2009-09-24 | — | — | US | disclosed |
| CN-101516372-A | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS INC (US) | 2009-08-26 | — | — | CN | disclosed |
| EP-1841738-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007081299-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252859-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | HTR5A, HTR3E, HTR1E | RORC 527/4885F10 2664/4885S1PR5 455/4885 |
| US-20110172283-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | HTR5A, HTR3E, HTR1E | RORC 527/4885F10 2664/4885S1PR5 455/4885 |
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | HTR5A, HTR3E, HTR1E | RORC 527/4885F10 2664/4885S1PR5 455/4885 |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | RORC 527/4885F10 2664/4885S1PR5 455/4885 |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | RORC 527/4885F10 2664/4885S1PR5 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.